Skip to content
lifestyle.newsblaze.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cerevance, Inc.
Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson’s Disease
October 7, 2026
Cerevance Appoints Karl Kieburtz, M.D., M.P.H., as Chief Medical Officer
October 5, 2026
Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027
May 12, 2026
Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting
April 9, 2026
Cerevance to Present Phase 2 Trial Results on OFF Time and Sleep‑Related Outcomes with Solengepras in Parkinson’s Disease at AD/PD™ 2026
March 10, 2026